UK Court Ruling A Blow For Pfizer And A Warning For Patentees
A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.
You may also be interested in...
Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.